Search results
How to Safely Discontinue Multiple Myeloma Maintenance Care
Medscape· 5 days agoNew research suggested that the key to safely discontinuing multiple myeloma maintenance therapy is...
'General Hospital' star John J York returns to work after 'aggressive' cancer treatment
Fox News via Yahoo News· 20 hours ago"General Hospital" star John York is ready to return to the show after undergoing bone marrow...
Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma
MedPage Today· 5 days agoMedPage Today brought together three expert leaders in the field: Moderator...
Gateway - The Root
The Root· 7 hours agoIn an exclusive interview with NBC News, Mutulu Shakur detailed life post-incarceration. Shakur, who is Tupac Shakur’s stepfather, was released on parole from federal prison on Dec. 16 after ...
CARsgen’s CAR T MM therapy shows early signs of efficacy in Phase I trial
Clinical Trials Arena via Yahoo Finance· 2 days agoShanghai based-biotech company CARsgen Therapeutics has announced that its CAR T cell candidate...
Head to Head Survey: Evaxion Biotech A/S (NASDAQ:EVAX) and Halozyme Therapeutics (NASDAQ:HALO)
ETF DAILY NEWS· 5 days agoHalozyme Therapeutics (NASDAQ:HALO – Get Free Report) and Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the ...
BioLineRx Ltd. to Post Q2 2024 Earnings of ($0.01) Per Share, Zacks Small Cap Forecasts...
ETF DAILY NEWS· 6 days agoBioLineRx Ltd. (NASDAQ:BLRX – Free Report) – Analysts at Zacks Small Cap issued their Q2 2024 earnings per share (EPS) estimates for BioLineRx in a research note issued on Monday, June 10th.
Entrada Therapeutics (NASDAQ:TRDA) versus BioLineRx (NASDAQ:BLRX) Head to Head Comparison
ETF DAILY NEWS· 4 days agoBioLineRx (NASDAQ:BLRX – Get Free Report) and Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast ...
Oppenheimer Lowers Cellectis (NASDAQ:CLLS) Price Target to $10.00
ETF DAILY NEWS· 5 days agoCellectis (NASDAQ:CLLS – Get Free Report) had its target price dropped by Oppenheimer from $11.00 to $10.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently ...
Fate Therapeutics (NASDAQ:FATE) Upgraded to Overweight by Piper Sandler
ETF DAILY NEWS· 1 day agoPiper Sandler upgraded shares of Fate Therapeutics (NASDAQ:FATE – Free Report) from a neutral rating to an overweight rating in a report published on Monday, MarketBeat.com reports. They currently ...